← FDA DRUG APPROVALS

FDA ANDA · ANDA207416

METHYLPHENIDATE HYDROCHLORIDE

Sponsor: ASCENT PHARMS INC

APPLICATION
ANDA207416
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-22
LATEST ACTION
2025-09-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

METHYLPHENIDATE HYDROCHLORIDEPrescription
METHYLPHENIDATE HYDROCHLORIDE 10MG · TABLET · ORAL
METHYLPHENIDATE HYDROCHLORIDEPrescription
METHYLPHENIDATE HYDROCHLORIDE 20MG · TABLET · ORAL
METHYLPHENIDATE HYDROCHLORIDEPrescription
METHYLPHENIDATE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2025-09-16Labeling · Supplement 15 · standardAP
2025-09-16Labeling · Supplement 13 · standardAP
2022-09-16Labeling · Supplement 6 · standardAP
2022-09-16Labeling · Supplement 9 · standardAP
2022-09-16Labeling · Supplement 5 · standardAP
2017-08-14Manufacturing (CMC) · Supplement 3 · unknownAP
2015-09-22UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →